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AbSTrACT
background Predictive tools to identify patients at 
risk for gene mutations related to pituitary adenomas 
are very helpful in clinical practice. We therefore aimed 
to develop and validate a reliable risk category system 
for aryl hydrocarbon receptor-interacting protein (AIP) 
mutations in patients with pituitary adenomas.
Methods an international cohort of 2227 subjects 
were consecutively recruited between 2007 and 2016, 
including patients with pituitary adenomas (familial and 
sporadic) and their relatives. all probands (n=1429) were 
screened for AIP mutations, and those diagnosed with a 
pituitary adenoma prospectively, as part of their clinical 
screening (n=24), were excluded from the analysis. 
Univariate analysis was performed comparing patients 
with and without AIP mutations. Based on a multivariate 
logistic regression model, six potential factors were 
identified for the development of a risk category system, 
classifying the individual risk into low-risk, moderate-risk 
and high-risk categories. an internal cross-validation test 
was used to validate the system.
results 1405 patients had a pituitary tumour, of 
which 43% had a positive family history, 55.5% 
had somatotrophinomas and 81.5% presented with 
macroadenoma. Overall, 134 patients had an AIP 
mutation (9.5%). We identified four independent 
predictors for the presence of an AIP mutation: age of 
onset providing an odds ratio (Or) of 14.34 for age 
0-18 years, family history (Or 10.85), growth hormone 
excess (Or 9.74) and large tumour size (Or 4.49). in 
our cohort, 71% of patients were identified as low risk 
(<5% risk of AIP mutation), 9.2% as moderate risk and 
20% as high risk (≥20% risk). excellent discrimination 
(c-statistic=0.87) and internal validation were achieved.
Conclusion We propose a user-friendly risk 
categorisation system that can reliably group patients 
into high-risk, moderate-risk and low-risk groups for 
the presence of AIP mutations, thus providing guidance 
in identifying patients at high risk of carrying an AIP 
mutation. this risk score is based on a cohort with high 
prevalence of AIP mutations and should be applied 
cautiously in other populations.
InTroduCTIon
Pituitary adenomas are relatively common lesions, 
present in approximately 17% of the general 
population,1 although clinically relevant disease is 
identified in only around 1:1000 subjects.2 3 Most 
pituitary adenomas are sporadic; however, familial 
cases are increasingly recognised, representing 
some 5% of all patients presenting with pituitary 
adenomas.4 Mutations in the aryl hydrocarbon 
receptor-interacting protein (AIP) gene predispose 
to the development of pituitary adenomas but with 
a low penetrance (20%–23%).5–8 AIP mutations 
can be identified either in the context of familial 
isolated pituitary adenomas (FIPA), defined by the 
presence of pituitary adenomas in two or more 
family members with no other syndromic features, 
or as simplex cases with a germline mutation but no 
known family history of the disease. The prevalence 
of AIP mutations is around 20% in FIPA kindreds,7 8 
while in sporadic pituitary adenomas, the preva-
lence ranges between 3.6% and 20%,9 10 depending 
on the age group studied.
More than 100 different ‘pathogenic’ or ‘likely 
pathogenic’11 germline AIP variants have been 
described (non-sense, missense, in frame deletion/
insertion, segmental duplication, large genomic 
deletion, frameshift, promoter, start codon and 
splice-site mutations8), while several variants 
are currently considered as having ‘unknown 
significance’.12
Although all types of pituitary adenomas 
have been described with germline AIP muta-
tions, patients with such mutations typically have 
young-onset growth hormone (GH)-secreting or 
GH-secreting and prolactin-secreting tumours 
with generally poor responsivity to conventional 
treatment, and aggressive behaviour compared 
with those with no recognised mutation,7 8 often 
requiring repeated surgery and radiotherapy and 
therefore needing close surveillance.7 13 14
Risk assessment for an AIP mutation has 
important clinical implications, and the genetic 
screening of family members allows for the iden-
tification of those at risk of developing aggres-
sive pituitary adenomas.8 15 16 Early diagnosis at a 
non-invasive stage can potentially lead to a higher 
chance of effective or curative treatment.8 15
There are no formal guidelines defining the 
criteria for genetic screening pituitary adenoma 
patients for AIP mutations, and currently the 
clinical decision for screening is based on expert 
recommendation.16 17 Identification of AIP muta-
tion-positive patients can lead to the detection of 
carriers with otherwise unrecognised disease,8 15 
potentially leading to a better prognosis. Our study 
aimed to develop and validate a risk category system 
to stratify patients with isolated pituitary adenomas 
for their risk of carrying AIP mutations. This risk 
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category system was designed to serve as an effective tool to aid 
clinical decision making and the identification of AIP mutation 
carriers in clinical practice.
MATerIAlS And MeThodS
Two thousand two hundred and twenty-seven subjects were 
included in our database from February 2007 to June 2016, 
including 1429 affected subjects with pituitary tumours and 798 
unaffected relatives. Subjects were recruited via the FIPA consor-
tium, an international research group. The data collected from 
medical records related to each individual patient were sent to 
our group, and the information was checked to confirm that all 
patients met the inclusion criteria. All subjects included signed 
the informed consent approved by the local ethics committee.
We included patients who presented with FIPA and patients 
diagnosed with apparently sporadic pituitary adenomas 
with disease onset at ≤30 years of age. In addition, we also 
included referred patients with sporadic adenomas and an 
age of onset >30 years. Patients with X-linked acrogigantism 
syndrome (XLAG)18 19 and patients who presented with other 
recognised syndromes such as multiple endocrine neoplasia 
type 1 or type 4, Carney complex and DICER1 syndrome, were 
excluded.20 These conditions were excluded on the basis of clin-
ical, biochemical and, in some cases, genetic testing, as appro-
priate. Although patients with XLAG also belong to the FIPA 
group, their clinical characteristics are so distinct that we felt 
that they should not be included in this risk prediction analysis. 
Patients diagnosed prospectively as a result of familial screening 
of known AIP mutations were also excluded from the analysis. 
Genetic screening for AIP mutations was performed using Sanger 
sequencing and multiplex ligation-dependent probe amplifica-
tion, as previously described.8 Genomic DNA was obtained from 
blood or saliva samples. The pathogenicity of the detected vari-
ants was assessed using the Mutation Taster (http://www. muta-
tiontaster. org/), Anovar21 and Variant Effect Predictor (VEP)22 in 
silico prediction programmes. We also included published clin-
ical and experimental data on the previously reported variants. 
Only pathogenic or likely pathogenic variants were considered 
as mutations.11
definition of variables
Patients were identified as affected if they had either (1) a 
pituitary tumour or (2) pituitary hyperplasia associated with 
hormone hypersecretion. FIPA was defined by the presence of 
pituitary adenomas in two or more members of a family with 
no other associated clinical features. The family history included 
assessment of all known ‘blood relatives’. The diagnoses were 
categorised as GH excess (including acromegaly and gigantism, 
with or without prolactin cosecretion), non-functioning pitu-
itary adenoma (NFPA), prolactinoma, Cushing’s disease and 
other diagnoses (any other type of functioning pituitary tumour). 
Macroadenomas were defined by tumour size ≥10 mm. Age of 
onset was defined as the age at presentation of the first symptom. 
Pituitary apoplexy was defined by a clinical history of haemor-
rhage and/or infarction of a pituitary adenoma.
Statistical analysis
The Shapiro-Wilks test was used to assess Gaussian distribution 
for continuous variables. Normally distributed variables were 
expressed as mean and SD and were analysed with the Student’s 
t-test. Median and IQR were used to describe non-normally 
distributed variables. These variables were analysed with the 
Mann-Whitney U test. Qualitative variables were expressed as 
percentage and analysed with the χ2 test to compare two or more 
groups; P<0.05 was taken as significant.
The following clinically relevant variables were included to 
generate the model: family history of pituitary tumours, gender, 
age of onset (categorised as ≤18 years, 19–30 years and >30 
years old), adenoma type (categorised as tumours secreting 
GH vs others), adenoma size (categorised as macroadenoma vs 
microadenoma or hyperplasia) and history of pituitary apoplexy. 
Interactions between all the studied variables were assessed 
with the likelihood ratio test. Variable selection was carried out 
through all possible equations methods, where every potential 
combination of the independent variables were computed and 
subsequently evaluated to assess the performance of the possible 
models.23 We selected the final model based on the Akaike infor-
mation criteria, area under the receiver operating character-
istic (ROC) curve and the Hosmer-Lemeshow tests. A logistic 
regression with the selected variables was performed, and results 
were expressed with an odds ratio (OR) and its 95% confidence 
interval (CI).
We arbitrarily categorised the risk of AIP mutation into 
low-risk (<5%), moderate-risk (5%–19%) and high-risk 
(≥20%) groups. Discrimination of the model was assessed 
with the c-statistic, and its calibration was assessed comparing 
observed versus model-derived AIP mutation risk and with the 
Hosmer-Lemeshow test. Finally, we assessed internal validity 
with a cross-validation procedure for a realistic estimation of 
the performance of the prediction model. Performance measures 
included R2 (explained variation of the model). Considering the 
size of our cohort, we randomly divided the sample in five equal-
sized parts, and we calculated the difference between our model 
and the resampling average. STATA software V.13.1 was used for 
statistical analysis.
reSulTS
Out of the 1429 pituitary adenoma patients, 153 carried an AIP 
mutation (10.7%). Out of the 343 relatives of patients with AIP 
mutations, 165 were carriers of an AIP mutation (48.1%). The 
clinical characteristics of the whole cohort are detailed in table 1.
Twenty-four family members were prospectively diagnosed 
with a pituitary adenoma, 19 of these carried an AIP muta-
tion (clinical characteristics are included in online supplemen-
tary table 1), while five belonged to AIP mutation-negative 
Table 1 Clinical characteristics of the whole cohort
Clinical characteristic n=1405*
AIP mutation, n (%) 134 (9.5)
Familial, n (%) 607 (43.2)
Gender, n (% male) 680 (48.5)
Diagnosis, n (%) 
  GH excess 767 (55.5) 
  NFPA 185 (13.4) 
  Prolactinoma 344 (24.9) 
  Cushing’s disease 74 (5.4) 
  Other diagnosis 11 (0.8) 
Age of onset (years) 27.1±13.1
Age at diagnosis (years) 30.8±13.4
Macroadenoma, n (%) 977 (81.5)
Extrasellar extension, n (%) 446 (60.1)
Pituitary apoplexy, n (%) 48 (3.9)
*Prospectively diagnosed patients excluded.
NFPA, non-functioning pituitary adenoma.
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families. Prospectively diagnosed patients were excluded from 
the analysis.
Six novel AIP mutations were found in one patient each, their 
characteristics are detailed in table 2. All AIP mutations identi-
fied are listed in online supplementary table 2.
The age of onset was significantly lower in AIP-positive 
versus AIP-negative patients (16 (14–24) (IQR) vs 25 (19-33) 
years, P<0.001), as was the age at diagnosis (21 (16–31) vs 29 
(22–38) years, P<0.001). Table 3 contains the comparison of 
clinical characteristics of AIP mutation-positive and AIP-negative 
patients.
The likelihood ratio test to evaluate interaction terms was 
non-significant (P=0.149), hence interaction terms were 
excluded from the model. The variable selection process 
suggested that pituitary apoplexy and gender should be removed 
from the model, as they did not add predictive power. A mark-
edly increased risk of an AIP mutation was associated with 
having a family history, a GH-excess adenoma, macroadenomas 
and young age of onset. The variables included in the predictive 
model are listed in table 4 in the order of their statistical strength 
for prediction. Good discriminative power was achieved with 
the area under the curve (AUC), reaching a value of 0.87 (95% 
CI 0.84 to 0.90) (figure 1). We stratified the risk of having an 
AIP mutation into low risk (<5%), moderate risk (5%–19%) and 
high risk (≥20%), based on our predictive model. Figure 2 shows 
stratified risks according to age, family history, tumour type and 
tumour size. In our cohort, enriched with familial, GH-secreting 
adenomas and young-onset cases, 70.8% of patients were iden-
tified as low risk, 9.2% as intermediate risk, while 20% were at 
high risk (risk ≥20%). Calibration results, comparing observed 
and model-predicted AIP mutation risk across the three risk 
groups, are depicted in the online supplementary figure 1. 
The Hosmer-Lemeshow test was non-significant (P=0.213), 
suggesting that the model is well calibrated.
Finally, the model showed good internal validation, as tested 
by the cross-validation technique, as the R2 shrinkage was <10% 
in absolute terms (from 0.294 to 0.223).
Table 2 Novel AIP mutations not previously reported. gnomAD: http://gnomad.broadinstitute.org/
AIP mutation MAF in gnomAd Variant type
In silico 
prediction* Probability score† Gender
Familial versus 
simplex diagnosis‡
Age at 
diagnosis
Age at 
onset
c.240_241delinsTG 
(p.M80_R81delinsIG)
Not reported Insertion 
deletion
High Disease causing 1 M Simplex Gigantism 8 5
c.333delC
(p.K112Rfs*44)
Not reported Frameshift High Disease causing 1 F Simplex Gigantism 9 7
c.376_377delCA 
(p.Q126Dfs*3)
Not reported Frameshift High Disease causing 1 F Simplex Gigantism 13 10
c.605A>G
(p.Y202C) §
Not reported Missense High Disease causing 0.99 M Simplex Gigantism 10 10
c.645+1G>C
(p.?)
Not reported Splicing High Disease causing 1 M Simplex Acromegaly 33 24
c.991T>C
(p.331Rext91)
Not reported Missense High Polymorphism 0.99 M Simplex Gigantism 16 12
*In silico prediction of probability of damaging mutation by Variant Effect Predictor and Anovar.
†Probability of pathogenic mutation by Mutation Taster.
‡All patients had macroadenoma, and none of them presented with pituitary apoplexy.
§This missense variant affects position 22 in the first tetratricopeptide domain of AIP, a well-conserved position in various tetratricopeptide domain proteins.32 38
AIP, aryl hydrocarbon receptor-interacting protein; MAF, minor allele frequency.
Table 3 Clinical characteristics comparing AIP-positive and AIP-
negative patients
Clinical characteristic AIP positive AIP negative P value
Familial, n (%) 89 (66.4) 518 (40.8) <0.001
Gender, n (% male) 83 (61.9) 597 (47.1) 0.001
Diagnosis, n (%) <0.001 
  GH excess 119 (88.8) 648 (52)
  NFPA 4 (3) 181 (14.5) 
  Prolactinoma 11 (8.2) 333 (26.7) 
  Cushing’s disease 0 74 (5.9) 
  Other diagnosis 0 11 (0.9) 
Age of onset (years and percentages) <0.001 
  0–18 79 (60.3) 259 (23.6) 
  19–30 33 (25.2) 506 (46) 
  >30 19 (14.5) 336 (30.5) 
Age at diagnosis (years and percentages) <0.001 
  0–18 53 (40.5) 163 (14.1) 
  19–30 44 (33.6) 497 (43) 
  >30 34 (26) 495 (42.9) 
Maximum diameter (mm)* 16 (10.7–25) 20 (11–30) 0.518
Macroadenoma, n (%) 112 (93.3) 865 (80.2) <0.001
Extrasellar extension, n (%) 52 (81.3) 394 (58.1) <0.001
Pituitary apoplexy, n (%) 12 (9.5) 36 (3.3) 0.001
Number of treatments* 2 (1–3) 1(1–2) 0.055
*Median and IQR.
NFPA, non-functioning pituitary adenoma.
Table 4 Logistic regression to generate a predictive model for AIP 
mutations*
Variable or (95% CI) P value
Age of onset
  >30 1 –
  0–18 14.34 (7.41 to 29.31) <0.001
  19–30 2.26 (1.17 to 4.35) 0.015
Positive family history 10.85 (6.48 to 18.16) <0.001
Diagnosis
  Others 1 –
  GH excess 9.74 (5.12 to 18.52) <0.001
  Size (macroadenoma) 4.49 (1.91 to 10.59) 0.001
*Variables are listed in the order of their statistical strength for prediction and each 
OR is adjusted for all the other variables.
AIP, aryl hydrocarbon receptor-interacting protein; GH, growth hormone.
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dISCuSSIon
Using state-of-the-art statistical methods applied to a large cohort 
of patients, we have identified four significant predictors for the 
presence of carrying an AIP mutation, and these are immediately 
accessible for routine clinical practice. Our data suggest that a 
positive family history, young age of onset, somatotroph tumour 
type and large tumour size can predict the risk of an AIP mutation 
according to our risk model, which has been validated in a large 
series of patients. Once a mutation carrier is identified, genetic 
testing can be performed for family members. The overall risk 
category of a kindred should be based on the risk score of the 
family member with the highest risk.
Despite the increasing number of genes associated with 
FIPA,5 18 formal guidelines do not currently include recommen-
dations for screening for AIP mutations,24 25 and therefore such 
screening is usually performed on the basis of expert recommen-
dations.16 17 26 27 These recommendations include patients who 
have (1) a family history of pituitary adenoma, (2) childhood-onset 
pituitary adenoma or (3) a pituitary somatotroph or lactotroph 
macroadenoma diagnosed before the age of 30 years; however, no 
data stratifying the different risks between these groups have been 
provided.9 10 16 17 Here we provide risk stratification for AIP muta-
tion positive patients, using a combination of clinical variables, all of 
which should be easily available at the time of diagnosis.
Not surprisingly, all the variables included in our AIP risk 
category system have been repeatedly reported as typical clinical 
features of AIP mutation-positive patients. The age of disease 
onset is the strongest predictive factor, with a maximum risk for 
an AIP mutation present in those patients who presented with 
an adenoma during childhood (OR 14.3 (95% CI 7.4 to 27.7), 
P<0.001). This result was expected, as the prevalence of AIP 
mutations in paediatric cases has been reported to be between 
6% and 23%.9 10 28 29 An age between 19 and 30 years (OR 2.3 
(95% CI 1.2 to 4.4), P=0.015) is also a strong predictor. In a 
previous study, among subjects with sporadic macroadenomas 
diagnosed before the age of 30 years, an AIP mutation was found 
in 11.7% overall, with a positive finding in 13.3% of patients 
with somatotrophinomas, 11.5% of those with prolactinomas 
and 6.3% of those with NFPAs.28 Taking the historical 10% risk 
cut-off for genetic screening,30 patients with familial GH-se-
creting macrodenoma, ≤30-year-old patients with familial 
GH-secreting microadenomas and sporadic childhood-onset 
GH-secreting macroadenomas are all above this threshold.
The second strongest predictive variable was positive family 
history of pituitary adenomas (OR 10.85 (95% CI 6.48 to 18.16), 
P<0.001). Although the majority of FIPA families have not yet 
had the causative gene identified, the largest available cohorts 
found that about 20% of FIPA kindreds harbour a heterozygous 
germline mutation in the AIP gene,7 8 with the overall rate being 
slightly higher in homogeneous versus heterogeneous kindreds 
(22.8% and 16.7%, respectively).16
GH excess is also a good independent predictor for AIP muta-
tions in our model (OR 9.74 (95% CI 5.12 to 18.52), P<0.001). 
One of the most important characteristics of patients with 
AIP mutations is the predominance of somatotrophinomas or 
somatolactotrophinomas, which account for around 80% of the 
cases. Prolactinomas and clinically NFPAs with positive GH and/
or PRL immunostaining are also well described, while ACTH-se-
creting or TSH-secreting adenomas or gonadotrophin positive 
or null cell NFPAs are very rare.31
In addition, we demonstrate that patients with macroad-
enomas have more than four times the risk of harbouring an 
AIP mutation compared with those with microadenomas (OR 
Figure 1 area under the receiver operating characteristic curve of the 
AIP mutation risk category system is 0.87 (95% ci 0.84 to 0.90), indicating 
an excellent discriminating power.
Figure 2 risk stratification for AIP mutations, classified as low risk 
(<5%), moderate risk (5%–19%) or high risk (≥20%). red: risk of 
AIP  mutation ≥20%; orange: risk of AIP  mutation between 5% and 
19%; green: risk of AIP  mutation <5%. gH, growth hormone; macro, 
macroadenoma; micro, microadenoma; simplex, patients with no 
known family history.
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4.49 (95% CI 1.91 to 10.59), P=0.001). Patients with AIP muta-
tions have macroadenomas in up to 90% of the cases, and their 
tumours are significantly larger and more frequently show an 
extrasellar extension compared with non-mutated familial8 and 
sporadic cases.6–8 Cases of double adenomas have also been 
described among AIP mutation positive patients,32 while pitu-
itary hyperplasia associated with GH excess33 34 is rare.
We also evaluated other clinical characteristics as possible 
predictors of AIP mutations. For instance, AIP mutation-positive 
patients frequently have a history of pituitary apoplexy, which 
is often the presenting feature.8 33 35 It is unclear whether this is 
due to the fact that these tumours are large and rapidly growing 
adenomas or whether an additional molecular mechanism 
renders these adenomas prone to apoplexy. In our study, pitu-
itary apoplexy was significantly more frequent in AIP mutated 
tumours than in negative cases (9.5% vs 3.3%, P=0.001); 
however, this variable did not add any predictive power to the 
risk model when we adjusted for the other variables.
Gender distribution was statistically significant in the univariate 
analysis (61.9% vs 47.1% males, P=0.001), but not when adjusted 
for the other variables. There is no clear consensus in the published 
literature about the gender distribution of AIP mutation-positive 
patients. While several studies reported an increased prevalence of 
male patients, ascertainment bias probably plays a role, as in large 
AIP mutation positive families the percentage of affected male 
patients was lower compared with sporadic AIP mutation-positive 
cases.8
Using the described model, we were able to stratify the risk of AIP 
mutation into low, moderate and high categories, and we believe 
this system can be an easy-to-use tool in clinical practice. The 
model performs well in terms of discrimination, calibration and 
internal validation. AUC was 0.87 (95% CI 0.84 to 0.90), where 
0.5 represents no discrimination and 1 represents perfect discrim-
ination, indicating that our model achieved an excellent discrim-
inatory power.36 Additionally, there were no obvious differences 
between observed and model-predicted AIP-positive patients. The 
Hosmer-Lemeshow test showed adequate goodness of fit of our 
model.36 We have validated our model using an internal cross-val-
idation procedure, one of the preferable methods when external 
validation is not feasible.36 The performance of the model was 
evaluated comparing the explained variation of the model (R2) in 
each of the five equal samples of the data and the total sample, 
achieving a reduction of R2 <10%.36 To the best of our knowledge, 
there is no other available AIP risk category system assessment in 
the literature for comparison.
Using our risk stratification model, we are able to: (1) describe 
the risk factors of carrying an AIP mutation; (2) quantify the 
predictive value for each risk factor adjusted by the others; and 
(3) estimate the individual risk of carrying an AIP mutation for 
a given patient. We expect this tool to be valuable for clinicians 
to improve the decision-making process of referring patients for 
genetic screening based on the individual risk of AIP mutation.
A screening algorithm based on the results of our risk category 
system is shown in figure 3. We need to emphasise that we used age 
of onset and not age of diagnosis for this analysis. This parameter 
is often more subjective and needs careful history taking, reviewing 
parents’ height and available photographic evidence of change of 
features. Patients with pituitary gigantism should be considered to 
have childhood-onset disease and offered screening.
There are some limitations inherent to our risk model. First, our 
risk score is based on a cohort enriched with familial, young-onset 
patients and GH-excess tumours as the number of AIP mutated 
patients in unselected cohorts is low.9 37 Although all possible diag-
nostic groups have some representation in our study, caution should 
be taken when extrapolating these results to a population with 
significantly different prevalence of AIP mutations than the one 
found in our cohort; this score ideally estimates the risk in patients 
where the mutation is already suspected. Second, the determina-
tion of age of onset can be subjective and subject to patient recall. 
Nevertheless, when comparing the model using the age of onset 
with the one produced using age of diagnosis, the AUC was signifi-
cantly better using age of onset rather than age at diagnosis; this 
might be explained due to the well-documented delay of diagnosis 
in patients with acromegaly. To minimise subjectivity, we catego-
rised the variable age of onset into three broad groups. Finally, it 
was not possible to perform an external validation of the model 
due to the relatively low number of cases with AIP mutations in our 
cohort (although it is the largest AIP mutation positive series so far 
described), which precluded splitting the sample into a derivation 
and validation group. However, we have successfully validated the 
model using an internal cross-validation method.
In summary, the risk category system we have developed has the 
potential for widespread use as it includes readily available predic-
tors. We believe this tool, ideally used in patients where the muta-
tion is already suspected, can facilitate the most effective use of 
genetic screening, which we believe is currently clearly underused, 
allowing the identification of patients who carry AIP mutations and 
providing the opportunity of early diagnosis in at-risk relatives.
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